[HTML][HTML] Targeting the extra-cellular matrix—tumor cell crosstalk for anti-cancer therapy: emerging alternatives to integrin inhibitors
G Lorusso, C Rüegg, F Kuonen - Frontiers in oncology, 2020 - frontiersin.org
The extracellular matrix (ECM) is a complex network composed of a multitude of different
macromolecules. ECM components typically provide a supportive structure to the tissue and …
macromolecules. ECM components typically provide a supportive structure to the tissue and …
Nrf2 inhibitor, brusatol in combination with trastuzumab exerts synergistic antitumor activity in HER2‐positive cancers by inhibiting Nrf2/HO‐1 and HER2‐AKT/ERK1/2 …
Y Yang, Z Tian, R Guo, F Ren - Oxidative medicine and cellular …, 2020 - Wiley Online Library
The HER2‐targeting antibody trastuzumab has shown effectiveness in treating HER2‐
positive breast and gastric cancers; however, its responses are limited. Currently, Nrf2 has …
positive breast and gastric cancers; however, its responses are limited. Currently, Nrf2 has …
Anti-tumor effects of osthole on different malignant tissues: A review of molecular mechanisms
M Ashrafizadeh, R Mohammadinejad… - Anti-Cancer Agents …, 2020 - ingentaconnect.com
Cancer management and/or treatment require a comprehensive understanding of the
molecular and signaling pathways involved. Recently, much attention has been directed to …
molecular and signaling pathways involved. Recently, much attention has been directed to …
YES1 activation induces acquired resistance to neratinib in HER2‐amplified breast and lung cancers
T Takeda, H Yamamoto, K Suzawa, S Tomida… - Cancer …, 2020 - Wiley Online Library
Molecular‐targeted therapies directed against human epidermal growth factor receptor 2
(HER2) are evolving for various cancers. Neratinib is an irreversible pan‐HER tyrosine …
(HER2) are evolving for various cancers. Neratinib is an irreversible pan‐HER tyrosine …
[HTML][HTML] Serum miR-222-3p as a double-edged sword in predicting efficacy and trastuzumab-induced cardiotoxicity for HER2-positive breast cancer patients receiving …
S Zhang, Y Wang, Y Wang, J Peng, C Yuan… - Frontiers in …, 2020 - frontiersin.org
Background: We aimed to explore whether the expression of serum miR-222-3p might
contribute to early prediction of therapeutic response, clinical outcomes, and adverse events …
contribute to early prediction of therapeutic response, clinical outcomes, and adverse events …